Dashboard
Manage Tickers

BMRN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-zimmer-biomet-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday
This Zimmer Biomet Analyst Is No Longer Bu...
11/06/2025 12:55:00

stifel-downgrades-biomarin-pharmaceutical-to-hold-lowers-price-target-to-61
Stifel Downgrades BioMarin Pharmaceutical ...
11/06/2025 12:48:05

Stifel analyst Paul Matteis downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Buy to Hold and lowers the price target fr...

bernstein-maintains-outperform-on-biomarin-pharmaceutical-lowers-price-target-to-88
Bernstein Maintains Outperform on BioMarin...
11/03/2025 12:47:13

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price t...

biomarin-pharmaceutical-announces-fda-has-accepted-its-supplemental-biologics-license-application-for-palynziq-to-treat-adolescents-aged-12-17-with-phenylketonuria-for-priority-review
BioMarin Pharmaceutical Announces FDA Has ...
10/29/2025 13:03:35

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Pr...

fda-accepts-biomarins-palynziq-supplemental-biologics-license-application-for-priority-review-to-include-adolescents-aged-12-17-with-phenylketonuria
FDA Accepts BioMarin's PALYNZIQ Supplement...
10/29/2025 13:01:29

truist-securities-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-80
Truist Securities Maintains Buy on BioMari...
10/28/2025 15:37:29

Truist Securities analyst Joon Lee maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target fr...

wells-fargo-maintains-overweight-on-biomarin-pharmaceutical-lowers-price-target-to-70
Wells Fargo Maintains Overweight on BioMar...
10/28/2025 15:21:16

Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price targ...

stifel-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-73
Stifel Maintains Buy on BioMarin Pharmaceu...
10/28/2025 13:57:44

Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $91 ...

biomarin-pharmaceutical-analysts-cut-their-forecasts-after-downbeat-earnings
Biomarin Pharmaceutical Analysts Cut Their...
10/28/2025 13:48:36

barclays-maintains-overweight-on-biomarin-pharmaceutical-lowers-price-target-to-80
Barclays Maintains Overweight on BioMarin ...
10/28/2025 13:07:44

Barclays analyst Gena Wang maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target fro...

hc-wainwright--co-maintains-neutral-on-biomarin-pharmaceutical-lowers-price-target-to-55
HC Wainwright & Co. Maintains Neutral on B...
10/28/2025 12:00:54

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers...

morgan-stanley-maintains-overweight-on-biomarin-pharmaceutical-lowers-price-target-to-98
Morgan Stanley Maintains Overweight on Bio...
10/28/2025 11:15:26

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the pri...

biomarin-pharmaceutical-lowers-fy2025-adj-eps-guidance-from-440-455-to-350-360-vs-325-est-raises-fy2025-sales-guidance-from-3125b-3200b-to-3150b-3200b-vs-3171b-est
BioMarin Pharmaceutical Lowers FY2025 Adj ...
10/27/2025 20:07:18

BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2025 Adj EPS guidance from $4.40-$4.55 to $3.50-$3.60 vs $3.25 analyst estimate....

biomarin-pharmaceutical-q3-adj-eps-012-misses-037-estimate-sales-776133m-miss-780629m-estimate
Biomarin Pharmaceutical Q3 Adj. EPS $0.12 ...
10/27/2025 20:05:24

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimat...

earnings-scheduled-for-october-27-2025
Earnings Scheduled For October 27, 2025
10/27/2025 08:32:18

Companies Reporting Before The Bell • Keurig Dr Pepper (NASDAQ:KDP) is projected to report quarterly earnings at $0.54 per sha...

what-to-expect-from-biomarin-pharmaceuticals-earnings
What to Expect from Biomarin Pharmaceutica...
10/24/2025 15:01:47

Biomarin Pharmaceutical (NASDAQ:BMRN) is preparing to release its quarterly earnings on Monday, 2025-10-27. Here's a brief...

is-biomarin-pharmaceutical-inc-gaining-or-losing-market-support
Is BioMarin Pharmaceutical Inc Gaining or ...
10/09/2025 19:00:50

6-analysts-assess-biomarin-pharmaceutical-what-you-need-to-know
6 Analysts Assess BioMarin Pharmaceutical:...
10/09/2025 13:00:54

jp-morgan-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-119
JP Morgan Maintains Overweight on BioMarin...
10/09/2025 12:51:55

JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target ...

biomarin-pharmaceutical-expects-q3-will-include-acquired-iprd-charges-of-221m-on-a-pre-tax-basis-due-to-inozyme-pharma-deal-for-q3-co-expects-charge-of-about-110-to-both-gaap-and-non-gaap-eps-due-to-inozyme-pharma-deal
BioMarin Pharmaceutical Expects Q3 Will In...
10/07/2025 21:25:04

https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/bmrn-20251007.htm

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION